Reported Data Supports the Potential Extension of HD-MAP Vaccine Delivery to Oncology Indications Recently published data generated by researchers at The University of Queensland and Vaxxas shows ...
The MarketWatch News Department was not involved in the creation of this content. -- Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via "patch" technology and utilizes ...
The research community's rapid acceptance of microarrays notwithstanding, technical challenges remain. Biochip developers continue to grapple with these issues while upgrading their offerings and ...
The Global Microarrays Market is expected to grow at a CAGR of 7.24% as the demand for drug discovery, disease diagnostics, and precision medicine continues to accelerate.Austin, Texas, Jan. 26, 2026 ...
"[People] had been developing Arabidopsis microarrays for a number of years, and these were some of the first papers that published high-quality data with real biological conclusions," says Chris Town ...
The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...
DUBLIN--(BUSINESS WIRE)--The "China Microarray Market Size, Share, Forecast, & Trend Analysis by Product, Application, End User- Forecast to 2031" report has been added to ResearchAndMarkets.com's ...
The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...
Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via “patch” technology and utilizes Micron’s first-in-class dissolvable microarray technology Research builds on Emory’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results